Skip to content

S. 2620 · 119th Congress (2025–2027)

REMEDY Act

This bill limits the scope of a 30-month stay on approval of a generic drug by the Food and Drug Administration (FDA) while patent litigation involving the reference (brand-name) drug is ongoing.

Generally, entities seeking approval of a new drug must provide the FDA with information on patents claiming the drug or a method of use. Entities seeking approval of a generic drug must certify for each such patent on the reference drug that (1) the patent has expired or will expire before the generic is marketed, or (2) the patent is invalid or inapplicable to the generic drug. If a generic drug applicant certifies that a patent is invalid or inapplicable and a patent infringement suit is timely brought, the FDA is prohibited from approving the generic for 30 months (unless the patent litigation is resolved sooner). Under current law, this 30-month stay applies to patent litigation on any number of patents on a reference drug, provided the patent information was filed with the FDA before the generic application.

Under the bill, when an entity applies to the FDA for approval of a new drug, the entity must select only one patent to be eligible for the 30-month stay. This selection may not be changed or amended. After the bill’s enactment, only patent litigation related to the reference drug’s selected patent may trigger the 30-month stay on approval of a generic.

Show official title

A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications.

Referred to committee

Latest actionReferred to committee

This bill’s path

This is S. 2620’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

Sponsor
Sen. Richard J. Durbin (D-IL)
Cosponsors
1 cosponsor

1 original · 0 later

  1. Sen. Bill Cassidy (R-LA)· Original · Jul 31, 2025
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest

    Referred to committee

    Congressional Record S5000

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Sources

Committees

  1. SenateHealth, Education, Labor, and PensionsReferred Jul 31, 2025

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Titles (3)
  1. REMEDY Act

    Display title, Short title · Introduced in Senate

  2. Reforming Evergreening and Manipulation that Extends Drug Years Act

    Short title · Introduced in Senate

  3. A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications.

    Official title · Introduced in Senate